相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial
Paul Baas et al.
LANCET (2021)
Overcoming Resistance to Tumor-Targeted and Immune-Targeted Therapies
Mihaela Aldea et al.
CANCER DISCOVERY (2021)
Efficacy, Safety, and Biomarker Analysis of Combined PD-L1 (Atezolizumab) and VEGF (Bevacizumab) Blockade in Advanced Malignant Peritoneal Mesothelioma
Kanwal Raghav et al.
CANCER DISCOVERY (2021)
A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti-PD-1 Agent Pembrolizumab
Prasad S. Adusumilli et al.
CANCER DISCOVERY (2021)
Prevalence of High Tumor Mutational Burden and Association With Survival in Patients With Less Common Solid Tumors
Changxia Shao et al.
JAMA NETWORK OPEN (2020)
Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline
Hedy L. Kindler et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Malignant peritoneal mesothelioma: a review
Glenn Broeckx et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2018)
Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors
Aurore Morello et al.
CANCER DISCOVERY (2016)
Comparison of genomic abnormality in malignant mesothelioma by the site of origin
Maiko Takeda et al.
JOURNAL OF CLINICAL PATHOLOGY (2014)
Copy Number Loss of the Interferon Gene Cluster in Melanomas Is Linked to Reduced T Cell Infiltrate and Poor Patient Prognosis
Peter S. Linsley et al.
PLOS ONE (2014)